石橋 宰

Dr. Osamu Ishibashi received his MSc from Tokyo Institute of Technology (Japan) in 1993. In the same year he joined a pharmaceutical company, Ciba-Geigy Japan (currently Novartis Pharma), and conducted basic research leading to the development of novel anti-osteoporosis drugs, including cathepsin K inhibitors. Based on the achievements in the company, he received his Ph.D from Nagaoka University of Technology (Japan) in 2000. He then accepted academic positions including a post-doctoral fellow in Max-Planck Institute of Biochemistry (Germany) and a senior scientist in Niigata University (Japan). In 2006, he joined Nippon Medical School as a senior assistant professor, and started new projects as to microRNA-mediated regulation of cell functions. In 2012, he accepted the current position (associate professor) in Osaka Prefecture University to develop studies as to genome-wide transcriptomics associated with various diseases including cancer, osteopathology and nephropathology.